Literature DB >> 10522226

Virulence factors of Actinobacillus actinomycetemcomitans.

P M Fives-Taylor1, D H Meyer, K P Mintz, C Brissette.   

Abstract

A. actinomycetemcomitans has clearly adapted well to its environs; its armamentarium of virulence factors (Table 2) ensures its survival in the oral cavity and enables it to promote disease. Factors that promote A. actinomycetemcomitans colonization and persistence in the oral cavity include adhesins, bacteriocins, invasins and antibiotic resistance. It can interact with and adhere to all components of the oral cavity (the tooth surface, other oral bacteria, epithelial cells or the extracellular matrix). The adherence is mediated by a number of distinct adhesins that are elements of the cell surface (outer membrane proteins, vesicles, fimbriae or amorphous material). A. actinomycetemcomitans enhances its chance of colonization by producing actinobacillin, an antibiotic that is active against both streptococci and Actinomyces, primary colonizers of the tooth surface. The fact that A. actinomycetemcomitans resistance to tetracyclines, a drug often used in the treatment of periodontal disease, is on the rise is an added weapon. Periodontal pathogens or their pathogenic products must be able to pass through the epithelial cell barrier in order to reach and cause destruction to underlying tissues (the gingiva, cementum, periodontal ligament and alveolar bone). A. actinomycetemcomitans is able to elicit its own uptake into epithelial cells and its spread to adjacent cells by usurping normal epithelial cell function. A. actinomycetemcomitans may utilize these remarkable mechanisms for host cell infection and migration to deeper tissues. A. actinomycetemcomitans also orchestrates its own survival by elaborating factors that interfere with the host's defense system (such as factors that kill phagocytes and impair lymphocyte activity, inhibit phagocytosis and phagocyte chemotaxis or interfere with antibody production). Once the organisms are firmly established in the gingiva, the host responds to the bacterial onslaught, especially to the bacterial lipopolysaccharide, by a marked and continual inflammatory response, which results in the destruction of the periodontal tissues. A. actinomycetemcomitans has at least three individual factors that cause bone resorption (lipopolysaccharide, proteolysis-sensitive factor and GroEL), as well as a number of activities (collagenase, fibroblast cytotoxin, etc.) that elicit detrimental effects on connective tissue and the extracellular matrix. It is of considerable interest to know that A. actinomycetemcomitans possesses so many virulence factors but unfortunate that only a few have been extensively studied. If we hope to understand and eradicate this pathogen, it is critical that in-depth investigations into the biochemistry, genetic expression, regulation and mechanisms of action of these factors be initiated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522226     DOI: 10.1111/j.1600-0757.1999.tb00161.x

Source DB:  PubMed          Journal:  Periodontol 2000        ISSN: 0906-6713            Impact factor:   7.589


  77 in total

1.  Secretion of RTX leukotoxin by Actinobacillus actinomycetemcomitans.

Authors:  S C Kachlany; D H Fine; D H Figurski
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Nonspecific adherence by Actinobacillus actinomycetemcomitans requires genes widespread in bacteria and archaea.

Authors:  S C Kachlany; P J Planet; M K Bhattacharjee; E Kollia; R DeSalle; D H Fine; D H Figurski
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

3.  Population structure and genetic diversity of Actinobacillus actinomycetemcomitans strains isolated from localized juvenile periodontitis patients.

Authors:  Jeffrey B Kaplan; Helen C Schreiner; David Furgang; Daniel H Fine
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

4.  Prevalence of cytolethal distending toxin production in periodontopathogenic bacteria.

Authors:  Ryousuke Yamano; Masaru Ohara; Shuichi Nishikubo; Tamaki Fujiwara; Toru Kawamoto; Yoko Ueno; Hitoshi Komatsuzawa; Katsuji Okuda; Hidemi Kurihara; Hidekazu Suginaka; Eric Oswald; Kazuo Tanne; Motoyuki Sugai
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 5.  Antimicrobial photodynamic therapy in the treatment of aggressive periodontitis: a systematic review and meta-analysis.

Authors:  Emmanuel Souza; Ana Cláudia Medeiros; Bruno César Gurgel; Carlos Sarmento
Journal:  Lasers Med Sci       Date:  2015-11-12       Impact factor: 3.161

6.  TdeA, a TolC-like protein required for toxin and drug export in Aggregatibacter (Actinobacillus) actinomycetemcomitans.

Authors:  Juan A Crosby; Scott C Kachlany
Journal:  Gene       Date:  2006-10-17       Impact factor: 3.688

7.  Immune response to cytolethal distending toxin of Aggregatibacter actinomycetemcomitans in periodontitis patients.

Authors:  E S Ando; L A De-Gennaro; M Faveri; M Feres; J M DiRienzo; M P A Mayer
Journal:  J Periodontal Res       Date:  2010-03-09       Impact factor: 4.419

8.  Genetic analysis of the requirement for flp-2, tadV, and rcpB in Actinobacillus actinomycetemcomitans biofilm formation.

Authors:  B A Perez; P J Planet; S C Kachlany; M Tomich; D H Fine; D H Figurski
Journal:  J Bacteriol       Date:  2006-09       Impact factor: 3.490

9.  Actinomycetemcomitin: a new bacteriocin produced by Aggregatibacter (Actinobacillus) actinomycetemcomitans.

Authors:  Francisca Lúcia Lima; Maria Auxiliadora Roque de Carvalho; Ana Carolina Morais Apolônio; Marcelo Porto Bemquerer; Marcelo Matos Santoro; Jamil Silvano Oliveira; Celuta Sales Alviano; Luiz de Macêdo Farias
Journal:  J Ind Microbiol Biotechnol       Date:  2007-11-08       Impact factor: 3.346

10.  Evaluation of the humoral immune response to the cytolethal distending toxin of Aggregatibacter actinomycetemcomitans Y4 in subjects with localized aggressive periodontitis.

Authors:  I Xynogala; A Volgina; J M DiRienzo; J Korostoff
Journal:  Oral Microbiol Immunol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.